X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through a licensing agreement, Apotex will market and distribute Verkazia (cyclosporine) ophthalmic emulsion, which is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis in children and adults.
Lead Product(s): Cyclosporine
Therapeutic Area: Ophthalmology Product Name: Verkazia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Apotex Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 15, 2024
Details:
Harrow diversified its portfolio of branded pharmaceutical products by acquiring 5 ophthalmic products, Ilevro, Nevanac, Vigamox, Maxidex, and Triesence. Triamcinolone acetonide is a synthetic corticosteroid indicated for sympathetic ophthalmia, temporal arteritis and uveitis.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Rare Diseases and Disorders Product Name: Triesence
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Novartis Pharmaceuticals Corporation
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition November 29, 2023
Details:
Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationorm PLUS.
Lead Product(s): Fluorometholone Acetate
Therapeutic Area: Ophthalmology Product Name: Flarex
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Santen Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 24, 2023
Details:
VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) is a fluoroquinolone antibiotic eye drop approved for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Lead Product(s): Moxifloxacin Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Vigamox
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationorm PLUS.
Lead Product(s): Fluorometholone Acetate
Therapeutic Area: Ophthalmology Product Name: Flarex
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Santen Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 17, 2023
Details:
Through acquisition, Harrow gains U.S. and Canadian commercial rights for Vevye (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ophthalmic solution prescription drug based on Novaliq’s proprietary EyeSol® water-free technology.
Lead Product(s): Cyclosporine
Therapeutic Area: Ophthalmology Product Name: Vevye
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Novaliq
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 17, 2023
Details:
Ilevro (nepafenac) is a non-steroidal anti-inflammatory drug (NSAID). It stops the body from making chemicals that cause inflammation, which helps lessen pain and swelling in the eye due to surgery.
Lead Product(s): Nepafenac
Therapeutic Area: Ophthalmology Product Name: Ilevro
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 23, 2023
Details:
The MKO melt (midazolam) is being marketed as an anesthetic medication for cataract surgery that has the advantage that it eliminates the need for an IV in 85% of patients although that number was established anecdotally.
Lead Product(s): Midazolam,Ketamine Hydrochloride,Ondansetron
Therapeutic Area: Ophthalmology Product Name: MKO Melt
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: iOR Partners
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 30, 2022
Details:
IOPIDINE 1% Ophthalmic Solution contains apraclonidine hydrochloride, an alpha-adrenergic agonist, in a sterile isotonic solution for topical application to the eye.
Lead Product(s): Apraclonidine Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Iopidine
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
FDA-approved IOPIDINE 1% is the gold standard for treating or preventing intraocular pressure during and after YAG laser eye surgery, which is required for about 40% of all prior cataract surgery patients.
Lead Product(s): Apraclonidine Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Iopidine
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 20, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
